The risk of cognitive impairment in older community-dwelling women after benzodiazepine use

Age and Ageing

Volumn 38, Issue 2, 2009, Pages 226-228

  Lagnaoui, Rajaa ^a   Tournier, Marie ^a,b,c   Moride, Yola ^b,c,d   Wolfson, Christina ^b,c   Ducruet, Thierry ^b   Bégaud, Bernard ^a   Moore, Nicholas ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE;

AGED; CANADA; CASE CONTROL STUDY; COGNITIVE DEFECT; COHORT ANALYSIS; COMMUNITY CARE; CONTROLLED STUDY; DEMENTIA; DRUG EXPOSURE; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 61449133204     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afn277     Document Type: Letter

References (17)

1. Curran HV, Collins R, Fletcher S et al. Older adults and withdrawal from benzodiazepine hypnotics in general practice: Effects on cognitive function, sleep, mood and quality of life. Psychol Med 2003; 33: 1223-37.
2. McAndrews MP, Weiss RT, Sandor P et al. Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacol Clin Exp 2003; 18: 51-57.
3. Barker MJ, Greenwood KM, Jackson M et al. Cognitive effects of long-term benzodiazepine use: A meta-analysis. CNS Drugs 2004; 18: 37-48.
4. Verdoux H, Lagnaoui R, Begaud B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med 2005; 35: 307-15.
5. Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: The Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 2002; 22: 285-93.
6. Lagnaoui R, Begaud B, Moore N et al. Benzodiazepine use and risk of dementia: A nested case-control study. J Clin Epidemiol 2002; 55: 314-8.
7. Fastbom J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 14-7.
8. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-7.
9. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: Study methods and prevalence of dementia. CMAJ 1994; 150: 899-913.
10. Canadian Study of Health and Aging Working Group. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994; 44: 2073-80.
11. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987; 48: 314-8.
12. Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. The Canadian Study of Health and Aging Working Group. Neurology 2000; 55: 66-73.
13. Wolfson C, Wolfson DB, Asgharian M et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111-6.
14. Fillenbaum GG. Multidimensional Functional Assessment of Older Adults: the Duke Older Americans Resources and Services Procedures. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
15. Egan M, Moride Y, Wolfson C et al. Long-term continuous use of benzodiazepines by older adults in Quebec: Prevalence, incidence and risk factors. J Am Geriatr Soc 2000; 48: 811-6.
16. Lagnaoui R, Moore N, Moride Y et al. Benzodiazepine utilization patterns in Alzheimer's disease patients. Pharmacoepidemiol Drug Saf 2003; 12: 511-5.
17. Lagnaoui R, Depont F, Fourrier A et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004; 60: 523-9.